REGENXBIO Inc. Investing Cash Flow
REGENXBIO Inc. (RGNX) reported Investing Cash Flow of $136.51 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-06
- REGENXBIO Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $65.92M.
- REGENXBIO Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $70.59M, a 57.76% increase year-over-year.
- REGENXBIO Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $37.54M, a 6.79% decline year-over-year.
- REGENXBIO Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $42.29M, a 15.86% decline year-over-year.
- REGENXBIO Inc. net cash provided by (used in) investing activities for fiscal 2025 was -$15.87M, a 115.34% decline from fiscal 2024.
- REGENXBIO Inc. net cash provided by (used in) investing activities for fiscal 2024 was $103.45M, a 45.82% decline from fiscal 2023.
- REGENXBIO Inc. net cash provided by (used in) investing activities for fiscal 2023 was $190.94M.
- REGENXBIO Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$11.93M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $65.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $136.51M 10-Q · filed 2026-08-06 | $174.05M derived: sum of 3 quarters · filed 2026-08-06 | $216.34M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $70.59M 10-Q · filed 2026-05-14 | $108.13M derived: sum of 2 quarters · filed 2026-05-14 | $150.41M derived: sum of 3 quarters · filed 2026-05-14 | $9.98M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $37.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $79.83M derived: sum of 2 quarters · filed 2026-03-05 | -$60.61M derived: sum of 3 quarters · filed 2026-08-06 | -$15.87M 10-K · filed 2026-03-05 |
| 2025-09-30 | $42.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$98.15M derived: sum of 2 quarters · filed 2026-08-06 | -$53.41M 10-Q · filed 2025-11-06 | -$13.13M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$140.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$95.69M 10-Q · filed 2026-08-06 | -$55.42M derived: sum of 3 quarters · filed 2026-08-06 | -$5.16M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $44.74M 10-Q · filed 2026-05-14 | $85.02M derived: sum of 2 quarters · filed 2026-05-14 | $135.27M derived: sum of 3 quarters · filed 2026-05-14 | $135.01M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $40.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $90.53M derived: sum of 2 quarters · filed 2026-03-05 | $90.26M derived: sum of 3 quarters · filed 2026-03-05 | $103.45M 10-K · filed 2026-03-05 |
| 2024-09-30 | $50.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $49.99M derived: sum of 2 quarters · filed 2025-11-06 | $63.17M 10-Q · filed 2025-11-06 | $97.15M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$268.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $12.91M 10-Q · filed 2025-08-07 | $46.89M derived: sum of 3 quarters · filed 2025-08-07 | $85.55M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $13.18M 10-Q · filed 2025-05-12 | $47.16M derived: sum of 2 quarters · filed 2025-05-12 | $85.81M derived: sum of 3 quarters · filed 2025-05-12 | $141.03M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $33.97M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $72.63M derived: sum of 2 quarters · filed 2025-03-13 | $127.85M derived: sum of 3 quarters · filed 2025-03-13 | $190.94M 10-K · filed 2025-03-13 |
| 2023-09-30 | $38.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $93.88M derived: sum of 2 quarters · filed 2024-11-06 | $156.97M 10-Q · filed 2024-11-06 | $183.67M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | $55.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $118.31M 10-Q · filed 2024-08-01 | $145.01M derived: sum of 3 quarters · filed 2025-03-13 | $198.06M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | $63.09M 10-Q · filed 2024-05-08 | $89.79M derived: sum of 2 quarters · filed 2025-03-13 | $142.84M derived: sum of 3 quarters · filed 2025-03-13 | $141.76M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | $26.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $79.74M derived: sum of 2 quarters · filed 2025-03-13 | $78.66M derived: sum of 3 quarters · filed 2025-03-13 | -$11.93M 10-K · filed 2025-03-13 |
| 2022-09-30 | $53.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $51.96M derived: sum of 2 quarters · filed 2023-11-08 | -$38.63M 10-Q · filed 2023-11-08 | -$254.99M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$1.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | -$91.67M 10-Q · filed 2023-08-02 | -$308.03M derived: sum of 3 quarters · filed 2024-02-27 | -$291.93M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$90.59M 10-Q · filed 2023-05-03 | -$306.95M derived: sum of 2 quarters · filed 2024-02-27 | -$290.85M derived: sum of 3 quarters · filed 2024-02-27 | -$283.05M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | -$216.36M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$200.26M derived: sum of 2 quarters · filed 2024-02-27 | -$192.46M derived: sum of 3 quarters · filed 2024-02-27 | -$406.64M 10-K · filed 2024-02-27 |
| 2021-09-30 | $16.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $23.90M derived: sum of 2 quarters · filed 2022-11-03 | -$190.28M 10-Q · filed 2022-11-03 | -$178.71M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $7.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$206.38M 10-Q · filed 2022-08-03 | -$194.81M derived: sum of 3 quarters · filed 2023-02-28 | -$160.82M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$214.18M 10-Q · filed 2022-05-04 | -$202.61M derived: sum of 2 quarters · filed 2023-02-28 | -$168.62M derived: sum of 3 quarters · filed 2023-02-28 | -$124.13M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $11.57M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $45.57M derived: sum of 2 quarters · filed 2023-02-28 | $90.05M derived: sum of 3 quarters · filed 2023-02-28 | $122.76M 10-K · filed 2023-02-28 |
| 2020-09-30 | $34.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $78.48M derived: sum of 2 quarters · filed 2021-11-02 | $111.19M 10-Q · filed 2021-11-02 | $125.34M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $44.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $77.19M 10-Q · filed 2021-08-09 | $91.34M derived: sum of 3 quarters · filed 2022-03-01 | $143.62M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $32.71M 10-Q · filed 2021-05-05 | $46.86M derived: sum of 2 quarters · filed 2022-03-01 | $99.14M derived: sum of 3 quarters · filed 2022-03-01 | $120.81M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $14.15M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $66.43M derived: sum of 2 quarters · filed 2022-03-01 | $88.10M derived: sum of 3 quarters · filed 2022-03-01 | $93.56M 10-K · filed 2022-03-01 |
| 2019-09-30 | $52.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $73.94M derived: sum of 2 quarters · filed 2020-11-04 | $79.41M 10-Q · filed 2020-11-04 | $12.22M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $21.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $27.13M 10-Q · filed 2020-08-06 | -$40.05M derived: sum of 3 quarters · filed 2021-03-01 | -$176.77M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $5.46M 10-Q · filed 2020-05-07 | -$61.72M derived: sum of 2 quarters · filed 2021-03-01 | -$198.44M derived: sum of 3 quarters · filed 2021-03-01 | -$236.81M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | -$67.18M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$203.91M derived: sum of 2 quarters · filed 2021-03-01 | -$242.27M derived: sum of 3 quarters · filed 2021-03-01 | -$279.36M 10-K · filed 2021-03-01 |
| 2018-09-30 | -$136.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | -$175.09M derived: sum of 2 quarters · filed 2019-11-05 | -$212.18M 10-Q · filed 2019-11-05 | -$213.32M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-06-30 | -$38.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$75.45M 10-Q · filed 2019-08-07 | -$76.60M derived: sum of 3 quarters · filed 2020-02-26 | -$57.83M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-03-31 | -$37.09M 10-Q · filed 2019-05-07 | -$38.23M derived: sum of 2 quarters · filed 2020-02-26 | -$19.46M derived: sum of 3 quarters · filed 2020-02-26 | |
| 2017-12-31 | -$1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $17.62M derived: sum of 2 quarters · filed 2020-02-26 | -$4.79M 10-K · filed 2020-02-26 | |
| 2017-09-30 | $18.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$3.65M 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | -$22.41M 10-Q · filed 2018-08-08 | |||
| 2016-12-31 | $19.39M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |